Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13389213 | 1.00 | LMNA (0.58) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL1099218 | 1.00 | LMNA (0.58) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL4558922 | 0.88 | PTGS2 (0.52) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL4935067 | 0.86 | LMNA (0.61) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL67237 | 0.84 | LMNA (0.59) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL65737 | 0.84 | LMNA (0.59) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL1715 | 0.84 | LMNA (0.59) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL20769804 | 0.84 | LMNA (0.59) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL29757088 | 0.84 | LMNA (0.59) | LMNAHSD17B10ALDH1A1POLBCRHBP | |
| SCHEMBL4560385 | 0.84 | CTSS (0.50) | LMNAHSD17B10ALDH1A1POLBKCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319670-A1 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues | PURDUE PHARMA L.P. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9549972-B2 | MHC-I restricted epitopes containing non-natural amino acid residues | PURDUE PHARMA L.P. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160022787-A1 | Peptide Immunogens | PURDUE PHARMA L.P. (US) | 2016-01-28 | — | — | US | disclosed |
| US-9109007-B2 | MHC-I restricted epitopes containing non-natural amino acid residues | PURDUE PHARMA L.P. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140050749-A1 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues | PURDUE PHARMA L.P. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8383094-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2264032-A2 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319670-A1 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues | MICA, HLA-DRB1, CD74 | LMNA 4141/4885HSD17B10 3799/4885ALDH1A1 3978/4885 |
| US-20160022787-A1 | Peptide Immunogens | MICA, HLA-DRB1, CD74 | LMNA 4776/4885HSD17B10 4199/4885ALDH1A1 4412/4885 |
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | LMNA 3159/4885HSD17B10 1305/4885ALDH1A1 1144/4885 |
| US-20140050749-A1 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues | MICA, TAP1, CD74 | LMNA 2733/4885HSD17B10 800/4885ALDH1A1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.